ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

This study is currently recruiting participants.
Verified December 2013 by Edwards Lifesciences
Information provided by (Responsible Party):
Edwards Lifesciences Identifier:
First received: December 18, 2012
Last updated: December 6, 2013
Last verified: December 2013

The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.

Condition Intervention
Aortic Stenosis
Mitral Stenosis
Aortic Valve Insufficiency
Mitral Valve Insufficiency
Heart Failure
Device: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of the Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform

Resource links provided by NLM:

Further study details as provided by Edwards Lifesciences:

Primary Outcome Measures:
  • Safety Endpoints [ Time Frame: When 400 patient years for each valve position has been achieved - approx. December 2016 ] [ Designated as safety issue: Yes ]

    Descriptive information of early rates and late linearized rates of:

    • Structural valve deterioration
    • Thromboembolism
    • Valve thrombosis
    • All bleeding/hemorrhage
    • Major bleeding/hemorrhage
    • All paravalvular leak
    • Major paravalvular leak
    • Non-structural valve deterioration
    • Endocarditis
    • All cause mortality
    • Trial valve-related mortality
    • Trial valve-related reoperation
    • Explant
    • Hemolysis

Secondary Outcome Measures:
  • Effectiveness Endpoints [ Time Frame: Up to 5-Years at each scheduled follow-up visit ] [ Designated as safety issue: No ]
    • Clinically acceptable hemodynamic performance confirmed by core lab evaluation of echocardiography
    • New York Heart Association (NY-HA) functional class compared to baseline
    • Change in Quality of Life questionnaire Short Form 12 version 2 (SF-12v2) from baseline/screening to POD 390

Estimated Enrollment: 650
Study Start Date: December 2012
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M
Aortic/Mitral valve replacement therapy
Device: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M
Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M

Detailed Description:

This is a prospective, non-randomized, non-controlled observational clinical trial. Up to 650 subjects will be enrolled at up to 30 participating clinical sites. The trial will include male and female patients, 18 years or older, requiring replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic or mitral valve. Patients will be followed and assessed after implant for up to 5 years.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is 18 years or older
  2. Provides written informed consent prior to trial procedures
  3. Is geographically stable and agrees to attend all follow-up assessments at the hospital of surgical services for up to 5 years
  4. Diagnosed with aortic or mitral valve disease requiring valve replacement based on pre- or intra- operative evaluation
  5. Scheduled to undergo planned aortic or mitral valve replacement with or without concomitant bypass surgery

Exclusion Criteria:

  1. Requires emergency surgery
  2. Requires multiple valve replacement/repair
  3. Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ
  4. Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)
  5. Requires surgical replacement of the aortic root
  6. Requires graft replacement of the ascending aorta
  7. Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to the scheduled aortic or mitral valve replacement surgery
  8. Has renal insufficiency as determined by creatinine (S-Cr) level ≥ 2.5 mg/dL or end-stage renal disease requiring chronic dialysis at screening visit
  9. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery
  10. Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery
  11. Has presence of non-cardiac disease limiting life expectancy to less than 12 months
  12. Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)
  13. Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism
  14. Exhibits left ventricular ejection fraction ≤ 20% as validated by diagnostic procedure within 30 days prior to planned valve surgery
  15. Echocardiographic evidence of an intracardiac mass, thrombus, or vegetation
  16. Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery
  17. Documented leukopenia (WBC < 3.5x 103/µL), acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L), thrombocytopenia (platelet count < 50x103/µL) or history of bleeding diathesis or coagulopathy
  18. Has prior organ transplant or is currently an organ transplant candidate
  19. Current or recent participation (within 6 weeks prior to surgery) in another investigational drug or device trial
  20. Was previously implanted with investigational device
  21. Pregnant (female subject of childbearing potential only), lactating or planning to become pregnant during the duration of participation in trial
  22. Currently incarcerated or unable to give voluntary informed consent
  23. Documented history of substance (drug or alcohol) abuse within the last 5 years prior to implant
  Contacts and Locations
Please refer to this study by its identifier: NCT01757665

Contact: Bruce Van Deman 949-250-2626
Contact: Gita Ghadimi, OD 949-250-5872

United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90033
Contact: Becky Lopez, RN    323-442-6226   
Contact: Candace Bart, RN    323-442-5898   
Principal Investigator: Vaughn Starnes, MD, PhD         
United States, Florida
Shands at the University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Debra Robertson, RN    352-273-5510   
Contact: Charles Klodell, MD    352-273-5501   
Principal Investigator: Charles Klodell, MD         
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Kim Baio, MSN    404-686-3374   
Contact: Renee Cook, RN    404-686-3364   
Principal Investigator: John Puskas, MD, FACS, FACC         
United States, Indiana
St. Vincent Medical Group Recruiting
Indianapolis, Indiana, United States, 46290
Contact: Lisa Barnett, RN    317-583-7804   
Contact: Andrew Scroggs, Research Director    317-338-9380   
Principal Investigator: David A Heimansohn, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Susie Page, RN    913-588-9720   
Contact: Dominique Dziedzic    913-945-6445   
Principal Investigator: George "Trip" Zorn, MD         
United States, Maryland
University of Maryland School of Medicine Recruiting
Baltimore, Maryland, United States, 21201
Contact: Robert Villanueva, MPA    410-328-9409   
Contact: Cindi Young, RN    410-328-8149   
Principal Investigator: James S Gammie, MD         
United States, Michigan
Spectrum Health Hospital Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Jeanine Holen, RN    616-391-5067   
Contact: Julie Bishop, RN    616-391-2727   
Principal Investigator: Tomasz A Timek, MD         
United States, New York
New York Presbyterian Hospital - Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Lyn Goldsmith, MA RN BSN CCRC    212-342-0261   
Contact: Amanda Alonso, CCRC    212-342-4539   
Principal Investigator: Allan Stewart, MD         
New York Weill Cornell Medical Center Recruiting
New York, New York, United States, 10021
Contact: Kim O'Brien, NP    212-746-5194   
Contact: Yury Rabotnikov, MD    212-746-5594   
Principal Investigator: Leonard Girardi, MD         
Mt. Sinai Medical Center Recruiting
New York, New York, United States, 10029
Contact: Ya-El Mandel-Portnoy, M. Sc    212-241-8905   
Contact: Robin Varghese, MD    212-659-9490   
Principal Investigator: David Adams, MD         
United States, Ohio
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Michelle Garcia, RN,BSN    216-444-7753   
Contact: Kathy Sankovic, RN, CCRP    216-445-6916   
Principal Investigator: Lars Svensson, MD, PhD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Tunu Magwe, MPH    713-798-8393   
Contact: Cynthia Boudreaux, M.Ed.    713-791-1414 ext 4041   
Principal Investigator: Todd K Rosengart, MD         
Krakowski Szpital Specjalistyczny im. Jana Pawla II Recruiting
Krakow, Poland, 31-202
Contact: Krzysztof Bartus, Dr. Med    +48 5022 94 250   
Contact: Maciek Bochenek, Dr. Med    +48 6065 15 870   
Principal Investigator: Jerzy Sadowski, Prof. Dr. Med         
Instytut Kardiologii im. Prymasa Tysiqclecia Stefana Recruiting
Warsaw, Poland, 04-628
Contact: Agata Bilewska, MD, PhD    +48(22)8154901   
Contact: Mariusz Kusmierczyk, MD, PhD    +48(22)3434610   
Principal Investigator: Jacek Rozanski, MD, PhD         
Sponsors and Collaborators
Edwards Lifesciences
Principal Investigator: John Puskas, MD Emory University Hospital Midtown
Principal Investigator: Lars Svensson, MD,PhD Organizational Affiliation: The Cleveland Clinic
  More Information

No publications provided

Responsible Party: Edwards Lifesciences Identifier: NCT01757665     History of Changes
Other Study ID Numbers: 2012-02
Study First Received: December 18, 2012
Last Updated: December 6, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Edwards Lifesciences:
Aortic valve replacement
Mitral valve replacement

Additional relevant MeSH terms:
Aortic Valve Insufficiency
Aortic Valve Stenosis
Constriction, Pathologic
Heart Failure
Mitral Valve Insufficiency
Mitral Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction
Pathological Conditions, Anatomical processed this record on April 17, 2014